ONK Therapeutics Alternatives & Competitors
12 companies similar to ONK Therapeutics — Pioneering optimally engineered NK cell therapies to cure patients with cancer.
Companies similar to ONK Therapeutics
Prescient Therapeutics
A clinical stage oncology company developing personalised medicine approaches to cancer; c...
Australia
Carisma Therapeutics
Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors
Philadelphia, United Stat...
Adicet Bio, Inc
A biotechnology company discovering and developing first-in-class allogeneic gamma delta C...
Redwood City, United Stat...
GammaDelta Therapeutics
GammaDelta Therapeutics focuses on using γδ T cells to improve survival rates of patients...
London, United Kingdom
Track all ONK Therapeutics competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Acepodia
POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER
Alameda, United States
Verismo Therapeutics
The team that invented the first FDA-approved CAR-T therapy is back to revolutionize the s...
Philadelphia, United Stat...
Bicara Therapeutics
Pioneering bifunctional antibodies for targeted tumor modulation
Boston, United States
Neogene Therapeutics
Pushing the frontier by pioneering next-generation engineered T cell receptor therapies fo...
Amsterdam, The Netherland...
ImmuneBridge
Bridging research and translation for a healthy future.
San Francisco, United Sta...
Harpoon Therapeutics
SPEARHEADING IMMUNOTHERAPIES
South San Francisco, Unit...
Marker Therapeutics, Inc.
Pioneering a Multi-Antigen Approach
Houston, United States
Lisata Therapeutics, Inc.
Targeted Therapy Delivered
United States
About ONK Therapeutics
ONK Therapeutics is a biotechnology startup focused on pioneering optimally engineered NK cell therapies to cure patients with cancer. The company, founded in 2015 in Ireland by Prof. O’Dwyer MD, has developed a next-generation off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies a...
NK Cell Therapies, Cancer Treatment, Cell Therapy Company, Off-the-shelf Therapy, Dual-targeted NK Cell Therapy, Hematological Malignancies, Solid Tumors, Chimeric Antigen Receptor (CAR), TNF Related Apoptosis Inducing Ligand Variant (TRAILv), Tumor Microenvironment, Immunotherapy, Translational Research, Oncology, Professor-founded Company
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches ONK Therapeutics and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at ONK Therapeutics on 12 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 11 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
